Next Article in Journal / Special Issue
Safety Analysis of Panax Ginseng in Randomized Clinical Trials: A Systematic Review
Previous Article in Journal
A Survey of Chemical Compositions and Biological Activities of Yemeni Aromatic Medicinal Plants
Previous Article in Special Issue
Disintegration Test of Health Food Products Containing Ginkgo Biloba L. or Vitex Agnus-Castus L. in the Japanese Market
Article Menu

Export Article

Open AccessArticle
Medicines 2015, 2(2), 93-105;

Studies on Pharmacokinetic Drug Interaction Potential of Vinpocetine

National Center for Natural Products Research, School of Pharmacy, The University of Mississippi, University, MS 38677, USA
Department of BioMolecular Sciences, School of Pharmacy, The University of Mississippi, University, MS 38677, USA
Department of Pharmacognosy, College of Pharmacy, King Saud University, Riyadh 12372, Saudi Arabia
Author to whom correspondence should be addressed.
Academic Editor: Il-Moo Chang
Received: 31 March 2015 / Revised: 26 May 2015 / Accepted: 2 June 2015 / Published: 5 June 2015
(This article belongs to the Special Issue Safety of Herbal Materials)
Full-Text   |   PDF [334 KB, uploaded 5 June 2015]   |  


Background: Vinpocetine, a semi-synthetic derivative of vincamine, is a popular dietary supplement used for the treatment of several central nervous system related disorders. Despite its wide use, no pharmacokinetic drug interaction studies are reported in the literature. Due to increasing use of dietary supplements in combination with conventional drugs, the risk of adverse effects is on the rise. As a preliminary step to predict a possibility of drug interaction during concomitant use of vinpocetine and conventional drugs, this study was carried out to evaluate the effects of vinpocetine on three main regulators of pharmacokinetic drug interactions namely, cytochromes P450 (CYPs), P-glycoprotein (P-gp), and Pregnane X receptor (PXR). Methods: Inhibition of CYPs was evaluated by employing recombinant enzymes. The inhibition of P-gp was determined by calcein-AM uptake method in transfected and wild type MDCKII cells. Modulation of PXR activity was monitored through a reporter gene assay in HepG2 cells. Results: Vinpocetine showed a strong inhibition of P-gp (EC50 8 µM) and a moderate inhibition of recombinant CYP3A4 and CYP2D6 (IC50 2.8 and 6.5 µM) with no activity towards CYP2C9, CYP2C19 and CYP1A2 enzymes. In HLM, competitive inhibition of CYP3A4 (IC50 54 and Ki 19 µM) and non-competitive inhibition of CYP2D6 (IC50 19 and Ki 26 µM) was observed. Activation of PXR was observed only at the highest tested concentration of vinpocetine (30 µM) while lower doses were ineffective. Conclusion: Strong inhibition of P-gp by vinpocetine is indicative of a possibility of drug interactions by altering the pharmacokinetics of drugs, which are the substrates of P-gp. However, the effects on CYPs and PXR indicate that vinpocetine may not affect CYP-mediated metabolism of drugs, as the inhibitory concentrations are much greater than the expected plasma concentrations in humans. View Full-Text
Keywords: vinpocetine; vincamine; pharmacokinetic drug interactions; PXR; CYP450 enzymes; P-gp vinpocetine; vincamine; pharmacokinetic drug interactions; PXR; CYP450 enzymes; P-gp

Figure 1

This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited (CC BY 4.0).

Share & Cite This Article

MDPI and ACS Style

Manda, V.K.; Avula, B.; Dale, O.R.; Chittiboyina, A.G.; Khan, I.A.; Walker, L.A.; Khan, S.I. Studies on Pharmacokinetic Drug Interaction Potential of Vinpocetine. Medicines 2015, 2, 93-105.

Show more citation formats Show less citations formats

Related Articles

Article Metrics

Article Access Statistics



[Return to top]
Medicines EISSN 2305-6320 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top